Welcome
Creating Novel Drugs For Debilitating CNS Diseases
biocrea discovers and develops novel drugs for the treatment of debilitating CNS diseases such as Alzheimer’s disease, schizophrenia, Huntington’s disease or Tourette’s syndrome.
The company’s team has an exceptional track record in the development of CNS drug candidates and of running extensive collaborative projects with major pharmaceutical companies such as GlaxoSmithKline and Wyeth (now Pfizer). biocrea is based in Radebeul, Germany.
Further information can be obtained from the corporate factsheet [download]
News
February 29, 2012 biocrea and Boehringer Ingelheim Conclude Asset Purchase Agreement
September 07, 2011 biocrea’s first-in-class PDE2 inhibitor demonstrates strong potential for the treatment of cognitive disorders
May 10, 2011 biocrea and Pfizer jointly presented details on novel PDE10 inhibitors at the 241st ACS National Meeting & Exposition
February 14, 2011 biocrea announces novel treatment opportunities for CNS diseases